pretickt

Is REGN a good stock to buy?

Regeneron Pharmaceuticals, Inc. · end-of-day data as of Nov 13, 2026

Regeneron
REGN · $98.82B
$955.47+0.4%
Nov 13, 2026 · close
$800$900SepOctNov9:3016:003 months +17.9%Nov 13 · close
▲ 7
  • ConsensusBuy · 29
  • P/E vs sector-34.5%
  • Trendbullish
  • MAs4 of 4
  • MA20×50Golden 9d ago
  • MACD5.33
  • Sector▲ +15.9%
Neutral
  • Earnings in76d
  • P/E21.1x
  • RSI68
  • Support-11.4%
  • Off 52w high-3.7%
  • Volume0.9x
  • Bollingerupper half
  • News0.00
  • FCF yield+3.6%
  • 52w range$592–$992
  • ATR+3.3%
  • Off ATH-21.1%
▼ 3
  • PT$893.88 -6.4%
  • P/E vs own+21.4%
  • Insiders-$51.9M

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Regeneron a good stock to buy?

Regeneron is strong on 3 of the 5 questions about the business. The price is about usual: 21.1 times its earnings, near its 3-year median of 18.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage some edge
  3. Economics very profitable
  4. Execution delivers
  5. Fragility sturdy
  6. Price about usual
DemandDo people want more of what it sells?steady

REGN sales growth revenue growth

+6%a year, for the last 3 years

Regeneron's sales grew 6% a year for 3 years, to $14.34B in fiscal 2025.

REGN analysts' forecast revenue estimates

+31%the sales they expect next fiscal year, on the last

Analysts expect Regeneron's sales to grow 31% to $18.75B in fiscal 2026 (19 analysts).

REGN competitors

pretickt analysis+19%its sales in 12 months, on a year before

Regeneron's sales grew 19% in the 12 months to Sep 30, 2026, faster than Moderna (+14%) and Vertex (+11%), slower than Alnylam (+56%) and Incyte (+25%).

REGN sales by business revenue by segment

51%of its sales from Collaboration Revenue

Collaboration Revenue brought Regeneron 51% of its sales in fiscal 2025; Product 44%.

Advantage moatIs it hard to copy?some edge

REGN return on capital ROIC

pretickt analysis15%earned before tax on the money invested in it

Regeneron earned 15% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Alnylam 31%, Incyte 29%, Vertex 20% and Moderna -30%.

REGN margin on each sale gross margin

86%left after making the product

Regeneron kept 86% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 81%.

EconomicsDoes it make good money?very profitable

REGN margin after costs profit margin

30%of sales left after running the business

Regeneron's operating margin was 30% in the 12 months to Sep 30, 2026, against 42% in fiscal 2022.

REGN cash generated free cash flow

$3.59Bcash left after investing, last 12 months

Regeneron generated $3.59B of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.

REGN profit per share

+9%in its last fiscal year

Regeneron's earnings per share grew 9% in fiscal 2025, to $41.56.

ExecutionDoes it deliver what it promises?delivers

REGN earnings vs estimates

7 of 8quarters above the analysts' estimate

Regeneron beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 30, 2026.

REGN insider selling

-$57.93Msold, net, by its executives in 12 months

Regeneron's executives and directors sold a net $57.93M of shares in the 12 months to Nov 13, 2026; none bought.

REGN number of employees

+2%more people in a year

Regeneron had 15,410 employees at the end of fiscal 2025, 2% more than a year before.

REGN CEO pay

$7.28Mfor fiscal 2025, 0% of it in stock and options

Regeneron paid its CEO $7.28M for fiscal 2025, 0% of it in stock and options.

Fragility risksCould something break it?sturdy

REGN financial health Altman Z-score

7.8Altman Z-score, safe above 3

Regeneron's Altman Z-score is 7.8 (Nov 13, 2026), above 3, where the safe zone starts.

REGN quality checks Piotroski score

6 of 9checks passed

Regeneron passes 6 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets, cash against profit and the current ratio.

REGN biggest customers

77%of sales from its 2 biggest customers

Two customers, unnamed in Regeneron's 10-K, made 77% of its sales in fiscal 2025.

REGN in past recessions

pretickt analysis+30%its sales in the worst one

Regeneron's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?about usual

REGN price vs profit P/E ratio

21.1×a year's earnings

Regeneron's P/E ratio is 21.1 (Nov 13, 2026), near its 3-year median of 18.6.

REGN price vs competitors

pretickt analysis21.1×a year's earnings, against its competitors

Investors pay 21.1 times Regeneron's earnings (Nov 13, 2026), more than for Alnylam (8.3), less than for Incyte (64.3) and Vertex (34.7).

REGN analysts' target price target

-6%to their average target

Analysts' average price target for Regeneron is $894, 6% below the Nov 13, 2026 close of $955.47.

REGN analyst ratings, 90 days

pretickt analysis
  • Argus Researchupgrade
  • UBSupgrade
2 up, 0 downratings raised and cut

In the 90 days to Nov 13, 2026, Argus Research and UBS upgraded Regeneron.

REGN growth priced in fair value

pretickt analysis+11%a year, for ten years, to be worth the price

At $955.47 a share, Regeneron's free cash flow must grow about 11% a year for ten years to be worth the price (Nov 13, 2026).

What is Regeneron's P/E ratio?

Regeneron's P/E ratio is 21.1 (Nov 13, 2026), near its 3-year median of 18.6. Investors pay 21.1 times Regeneron's earnings (Nov 13, 2026), more than for Alnylam (8.3), less than for Incyte (64.3) and Vertex (34.7).

Who are Regeneron's biggest competitors?

pretickt compares Regeneron with Moderna, Vertex, Incyte and Alnylam. Regeneron's sales grew 19% in the 12 months to Sep 30, 2026, faster than Moderna (+14%) and Vertex (+11%), slower than Alnylam (+56%) and Incyte (+25%).

Is Regeneron profitable?

Regeneron's operating margin was 30% in the 12 months to Sep 30, 2026, against 42% in fiscal 2022. Regeneron generated $3.59B of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.

Are insiders selling Regeneron stock?

Regeneron's executives and directors sold a net $57.93M of shares in the 12 months to Nov 13, 2026; none bought.

How does Regeneron make money?

Collaboration Revenue brought Regeneron 51% of its sales in fiscal 2025; Product 44%.

How many employees does Regeneron have?

Regeneron had 15,410 employees at the end of fiscal 2025, 2% more than a year before.

Who are Regeneron's biggest customers?

Two customers, unnamed in Regeneron's 10-K, made 77% of its sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.